Solifenacin Succinate

琥珀酸索利那新

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameSolifenacin Succinate
Drug Alias Namesolifenacina索非那新Solifenacinum索菲那新琥珀酸索非那新 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsUrinary Incontinence, UrgeUrinary Bladder, OveractiveUrologic Diseases
Global Approved IndicationsUrinary Bladder, Overactive
Approved Indications in ChinaUrinary Bladder, Overactive
Original Approved Country/TerritoryUnited States
Original Approved Date2004/11/19
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesQingdao Baheal Medical IncAstellas Pharma Europe BvAstellas Pharma Inc
Inactive CompaniesAstellas Pharma Us IncUniversity of ZurichLahey Clinic Inc +[5] 
Active IndicationsUrinary Bladder, Overactive
Inactive IndicationsUrinary Incontinence, UrgeUrologic Diseases

Other Information

ATC CodeG04BD08
Related LinksWikipediaDrugBankKEGG